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Hepatic Effects of a Phthalate Ester
Plasticizer Leached from
PoIy(vinyl Chloride) Blood Bags
Following Transfusion
by Sherwin V. Kevy* and May S. Jacobson*
The effects of di(2-ethylhexyl) phthalate (DEHP) on hepatic function and histology were
evaluated in the rhesus monkey undergoing platelet and plasma transfusion. The average
cumulative amount infused in one year is comparable to that received by patients who undergo
chronic transfusion. Abnormalities in hepatic scan and BSP kinetics persisted for up to 26
months after transfusion, as did histologic abnormalities. Patients undergoing maintenance
hemodialysis receive a yearly dose of DEHP which is 10-20 times that which produced
hepatotoxicity in the transfused rhesus.
Theplasticizer di(2-ethylhexyl) phthalate (DEHP)
is incorporated into poly(vinyl chloride) (PVC)
medical devices to produce flexibility. PVC medical
devices such as blood bags and indwelling intrave-
nous catheters contain up to 40% by weight of
DEHP. This material is leached from PVC byblood
andlipoprotein-containing solutions (1). This solubi-
lization is time- and temperature-dependent (1).
Previous studies have demonstrated DEHP in the
tissues ofmultitransfused patients and in neonates
whose only exposure was indwelling umbilical cath-
eters (2, 3).
Jacobson and Kevy (4) have demonstrated that
DEHP levels of5 mg/dl, the concentration found in
whole blood stored for 21 days at 4°C and in
platelets stored at 22°C for 24 hr, significantly
inhibits the growth ofhuman diploid fibroblasts. As
a consequence ofthis finding, rhesus monkeys were
used in a chronic transfusion study in which PVC
blood bags were compared with those made of
polyethylene.
The rhesus monkey was chosen as the animal
model, since there is marked species difference in
the metabolism of DEHP. Their baseline serum
protein analysis and agarose electrophoresis pat-
tern are normalinterms ofhumanvalues except for
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the orosomucoid level which is slightly lower. In
addition they behave similarly to both children and
adults as far as compartmentalization analysis of
bromosulfophthalein (BSP) kinetics and hepatic
99mTechnetium-labeled sulfur colloid scanning tech-
niques.
These animals were transfused with either plate-
let-rich or platelet-poor plasma in a manner identi-
cal to that utilized in clinical medicine. This is an
extremely critical point, because virtually all the
toxicology literature relative to DEHP is based
upon rodent exposure in a manner which in no way
mimics the way the human is exposed via transfu-
sion of blood products or renal dialysis.
Materials and Methods
Experimental Groups
Immature rhesus monkeys approximately six
months old and weighingless than 5 lb were divided
into the four following groups.
PVCPlatelet-Rich Plasma (PRP) Transfused.
Three rhesus monkeys were transfused weekly for
one year with 15 ml of PRP stored for 48 hr at
22°C, and two monkeys received PRP stored at
40C.
PVCPlatelet-PoorPlasma(Plasma) Transfused.
Two monkeys were transfused biweekly for 658
months with 15 ml of plasma stored at 22°C for 5
days. Even though this is no longer standard blood
bank practice, plasma was stored at room tempera-
ture to maximize the leaching of DEHP.
Nontransfused Controls. Three monkeys lived
in the same environment and underwent the same
test procedures as the experimental rhesus.
TransfusedControls. Twomonkeys were trans-
fused weekly for 6 months with 15 ml of PRP
stored for 48 hr at 22°C in polyethylene blood bags.
An aliquot of each transfusion was quantitated
for DEHP content.
Preparation of Platelet-Rich Plasma
Adult donor monkeys were plasmapheresed bi-
weekly to obtain platelet-rich plasma. Blood, 100
ml, was collected into a 150 ml PVC orpolyethylene
blood pack aseptically ifiled with 16 ml ACD antico-
agulant. The blood was centrifuged in a SBV No. 1
International centrifuge at 500 g at room tempera-
ture for 10 min, and the platelet-rich plasma was
aseptically transferred into a second 150 ml PVC or
polyethylene transfer pack. These packs were then
stored at 4 or 22°C for 48 hr. The average platelet
count in each bag was 150,000/mm3. The red cells
were returned to the donor monkeys.
Preparation of Plasma
Adult donor monkeys were plasmapheresed into
PVC blood packs as detailed above, except that the
whole blood was centrifuged at 2520 g for 10 min in
a RC-3 Sorvall centrifuge. The plasma was trans-
ferred into a PVC transfer pack and stored at 22°C
for up to 5 days. Each unit of plasma was tested
and found to be platelet free.
DEHP Quantitation
Levels of DEHP in blood products, blood and
tissue were determined by gas chromatography
with the use of our modification of the method of
Jaeger (4). The sensitivity of the assay is 0.1 ppm
(parts per million).
DEHP Dosage
The amount ofDEHP received by an experimen-
tal animal was calculated as the number of millili-
ters of stored blood component received times its
DEHP concentration. The total amount of DEHP





9'9Technetium-labeled sulfur colloid provides sta-
ble count rates, is short-lived, and has favorable
radiationdosimetry (5). Eachrhesusmonkeyreceived
99mTc at dose of0.015 mCi/kg body weight. Within
45 min after injection, the abdomen was scanned.
Peak counts were recorded over the substance of
the liver and spleen for 3 min and repeated five
times. The hepatosplenicratiowasthendetermined
fromthe mean counts overthe liverand the spleen.
Sulfobromophthalein (BSP) Transport
Sulfobromophthalein (BSP) transport was evalu-
ated by the method ofQuarfordt and associates (6).
Each study was performed after at least a 12-hr
fast. BSP was injected intravenously in a dose of5
mg/kg of body weight. Sequential blood samples
were obtained from the arm opposite that used for
injection. Zero time for the study was set at the
midpoint ofthe injection, which took an average of
30 sec to complete. Blood samples were obtained
prior to injection for BSP recovery studies, then at
3-min intervals for 30 min, and thereafter at 15-min
intervals for up to 2 hr. After the final blood sam-
ple, urine was collected for BSP recovery.
The plasma disappearance curve following a sin-
gle injection of BSP was analyzed by a computer
technique fordeterminingcompartmental flow. The
method computes the hepatic removal rate (HRR),
hepatic to plasma reflux rate (H-PRR), the biliary
secretory rate (BSR), and the urinary excretion
rate (UER) by means ofthe simulation analysis and
modelingtechnique ofBerman and associates, with
the use ofthe SAAM digital computer program on
an IBM 370-5165 computer (7). These rates are
expressed as the fractional rate (i.e., percent trans-
ported) per minute.
The model was verified in the rhesus monkey by
measurement ofthe disappearance ofdye from the
plasma and quantitation ofthe concentration ofdye
excreted in the bile and urine. The bile samples
were obtained by cannulation of the common bile
duct. The experimentally observed values were
plotted along with the computer-calculated values
and the curves were superimposed. An injected
dose was established which would not saturate the
transport processes. Data obtained by these meth-
ods were compared to previously reported studies
by us (8) in normal children and adults and children
with cystic fibrosis (CF).DEHP HEPATOTOXICITY FOLLOWING TRANSFUSION
Histopathology
Multiple surgical liver biopsies were performed
on all transfused and nontransfused monkeys. In
order to ensure adequate sampling for all studies, a
wedge biopsy was obtained on each occasion. Tis-
sues were rapidly fixed in formalin and embedded
in paraffin. Sections were stained by hematoxylin-
eosin, periodicacid-Schiff, periodic acid-Schiff-alcohol
and Sudan Black. All preparations were examined
in blinded fashion by four observers.
Results
DEHP Dosage
At the start ofthis study ten consecutive patients
were identified who predictably would be multi-
transfused. During the course of one year, each
unit ofred cells, whole blood, plasma and platelets
was quantitated for DEHP. The amount of DEHP
the patients received ranged from 56 to 1500 mg or
2.1 to 27.5 mg/kg. During their one-year period of
transfusion the group infused with platelet-rich
plasma stored at 22°C received 76.8-96.0 mg of
DEHP or 24-30 mg/kg, those transfused with plate-
let-rich plasma stored at 4°C received 20.5-27.0 mg
or 6.6-8.7 mg/kg and those infused with plasma 108
mg or 33 mg/kg.
Assessment of Liver Function
99mTcSulfurColloidLiver-SpleenScans. Severe
or moderate impairment ofhepatic perfusion and/or
infiltration are detected by irregular distribution of
tracer within the liver. Milder forms of parenchy-
mal disease can be quantitated by determination of
the distribution ratio of radiocolloid between liver
and spleen. Each animal served as its own control.
All subsequent determinations ofthe hepatosplenic
ratio were compared to the baseline ratio obtained
prior to transfusion. Liver/spleen activity ratios
were calculated assuming the spleen to be one. A
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ratio was considered abnormal ifthere was at least
a 30% decrease from the baseline level.
The results ofthe scanning studies in allmonkeys
are shown in Table 1. All rhesus transfused with
platelets stored in PVC had a significant decrease
in ratio throughout the period oftransfusion thera-
py. One rhesus in each of the platelet transfusion
groups were sacrificed at varying intervals during
this study to determine the DEHP organ content.
Three of the five surviving monkeys who were
transfused from PVC-DEHP blood bags demon-
strated abnormal scans for up to the 26 months
post-transfusion thatthey were followed duringthe
course ofthis study.
There were nochangesinthehepatosplenicratios
in the monkeys transfused with platelets stored in
polyethylene or in the nontransfused controls.
BSP Transport. The plasma disappearance
curves for BSP and the data from the two-com-
partment model of Quarfordt provide a very sensi-
tive indicator of subclinical liver disease. We have
demonstrated that the transport of BSP in the
normal monkey and the normal human being are
identical. The normal immature rhesus monkey and
the normal child have a single exponential curve,
whereas the normal adult rhesus monkey and the
normal adult human have a biexponential curve.
The change in the plasma BSP disappearance
curve is proportional to the degree ofliver involve-
ment. A child with cyctic fibrosis (CF) who has no
evidence ofhepatomegaly and normal liver function
demonstrates a single exponential disappearance
curve identical to that of a normal child. The child
with CF who has hepatomegaly and biopsy docu-
mented liverpathology demonstrates abiexponential
disappearance curve, even though SGOT, SGPT,
alkaline phosphatase, bilirubin and standard BSP
tests arenormal. Thedevelopmentofabiexponential
disappearance curve in a child or immature subhu-
manprimate, therefore, serves as asensitivemarker
of hepatic dysfunction and is considered abnormal.
One can also distinguish in the adult the difference
between anormalbiexponentialdisappearance curve
and that produced by liver disease (8).
Table 1. Rhesus liver/spleen activity ratios following 99m Tc sulfur colloid infusion.
Abnormal/normal
Transfusion interval Interval after transfusion
Rhesus group Baseline 6 mo. 12 mo. 5 mo. 14 mo. 26 mo.
Nontransfused 0/3 0/3 0/3 0/3 0/3 0/3
220C - PRP - PVC 0/3 3/3 3/3 2/3 2/3 1/2
40C - PRP - PVC 0/2 2/2 2/2 1/1 1/1 1/1
Plasma - PVC 0/2 1/2 - 1/2 1/2 1/2
PRP - Polyethylene 0/2 0/2 0/2 0/2 0/2 0/260
The results ofthe compartmental analysis ofBSP
kinetics in the transfused and nontransfused imma-
ture rhesus monkeys are shown in Table 2. A BSP
analysis was considered abnormal ifthe disappear-
ance curve was biexponential. The monkeys trans-
fused with platelets stored in polyethylene and the
nontransfused controls did not exhibit any abnor-
malities throughout the course of this study. Four
ofthe five monkeys transfused with platelets stored
in PVC exhibited abnormal disappearance curves
following one year of platelet transfusions. This
persisted in three of the four remaining rhesus
monkeys 14 months after transfusion and in one
rhesus 26 months following cessation of transfu-
sions. Both rhesus transfused with plasma stored in
PVC had abnonnal BSP disappearance curvesimme-
diately following the six months of transfusion.
These reverted to normal within five months follow-
ing the cessation of transfusions.
LiverHistopathology. Abiopsy wasconsidered
abnormal when at least two ofthe followingfindings
were present: (1) foci ofparenchymal necrosis (aggre-
gates of chronic inflammatory cells and Kupffer
cells in the parenchymal with degenerating hepato-
cytes); (2) vacuolization ofKupffer cells; (3) chronic
inflammatory cell infiltrates; and (4) prominence
and/or increase in the number of Kupffer cells and
the presence ofbinucleate cells. At no time during
thisstudy were anyhistologicabnormalitiesidentified
in liver biopsies of nontransfused or polyethylene-
transfused control monkeys.
All of the animals transfused with platelets or
plasma stored in PVC demonstrated histologic
abnormalities throughout the follow-up period.
Figure 1 demonstrates finding obtained in biopsy
24 months following cessation of transfusion in a
monkey who had received platelets stored at 4°C.
Figure 2 demonstrates .the persisting histologic
findings obtained at necropsy 32 months after the
cessation of transfusions in one of the monkeys
transfused with platelet-rich plasma stored at22°C.
Histologic changes at this time were character-
ized by aggregates of inflammatory cells, hepato-
cyte degeneration, and multinucleated and binucle-
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ated giant cells. These findings persisted despite
the fact that no DEHP was detected in liver tissue
at the time of necropsy.
Tissue Levels of DEHP
One ofthe inherent difficulties ofliver biopsies is
that only small specimens can be obtained. Tissue
samples obtained at biopsy averaged 225 mg wet
weight (range 100-400 mg). The limit ofsensitivity
of our analysis for DEHP by G.C. is 0.1 ppm. Any
samples with DEHP contents of 1.4 ppm to 1.5
ppm, levels well above background, were consid-
ered to have only a trace amount. Table 3 lists the
DEHP content of liver tissue obtained both at
biopsy and necropsy.
As shown in Table 3, the initial biopsies ofall the
PVCtransfusedrhesuscontained significantamounts
of DEHP. The nontransfused and polyethylene-
transfused monkeys had no detectable DEHP. The
five month follow-up samples contained concentra-
tions similar to those initially measured with the
exception of one PRP-transfused monkey and the
two plasma-transfused animals that only had trace
amounts of DEHP. At the 14 month follow-up
biopsy of the PRP animals, three had only trace
amounts ofDEHP, and one had no detectable level.
Since these samples were in the lower range ofthe
sensitivity of our assay for DEHP, we sacrificed
one ofthe animals (rhesus "G"). The tissue samples
utilized ranged from 2.5 to 4.0 g wet weight.
Significant levels of DEHP were found in the liver,
testis, heart and omental fat. The total residual
organ level, excluding fat, was less than one per-
cent of the dose administered.
DEHP was notdetected inliversamples obtained
at necropsy 32 months after transfusion, despite
thepersistenceofabnormalhistologicfindings. Unfor-
tunately, none ofthe samples were analyzed for the
monoester (MEHP).
Hemodialysis Studies
Since the rate ofleaching of DEHP from PVC is
dependent on the temperature and lipid content of
Table 2. Rhesus BSP kinetics.
Abnormal/normal
Transfusion interval Interval after transfusion
Rhesus group Baseline 6 mo. 12 mo. 5 mo. 14 mo. 26 mo.
Nontransfused 0/3 0/3 0/3 0/3 0/3 0/3
220C - PRP - PVC 0/3 3/3 3/3 2/3 2/3 1/2
40C - PRP - PVC 0/2 0/2 1/2 1/1 1/1 0/1
Plasma - PVC 0/2 2/2 - 0/2 0/2 0/2
PRP - Polyethylene 0/2 0/2 0/2 0/2 0/2 0/2DEHP HEPATOTOXICITY FOLLOWING TRANSFUSION
(A) (B)
f'IGURE 1. Biopsy 26 months after cessation of transfusions: (A) rhesus D received platelet-rich plasma stored for 48 hr at 22°C in
PVC (100 x); (B) rhesus D; areas shown demonstrate binucleate cells, hepatocyte necrosis and degenerating hepatocytes (400 x ).
(A) (B)
FIGURE 2. Necropsy 32 months after cessation of transfusions: (A) 100x; (B) 400x. Areas shown demonstrate aggregates of
inflammatory cells, hepatocyte necrosis and binucleate cells. DEHP content: none detected.
Table 3. DEHP content in liver of biopsied monkeys.a
DEHP content, Rug/g wet weight of liver
Interval after transfusion
Total DEHP Initial 32 mo.
Animals Procedure infused, mg biopsy 5 mo. 14 mo. 26 mo. (necropsy)
B NTb 0 NDC ND ND ND ND
C NT 0 ND ND ND ND ND
M NT 0 ND ND ND ND ND
D 220C (PVC)-PRP 74.80 3.0 Trace ND 6.7 ND
F 220C (PVC)-PRP 96.00 5.0 3.8 Trace ND ND
G 220C (PVC)-PRP 78.72 10.0 9.2 0.7 (Necropsy) Deceased
E 40C (PVC)-PRP 27.00 1.0 1.8 Deceased
H 40C (PVC)-PRP 20.52 1.5 3.1 Trace Deceased
S 22°C (PVC)Plasma 96.00 10.1 Trace Trace ND (Necropsy)
T 220C (PVC)Plasma 108.00 18.1 Trace 18.7 Trace (Necropsy)
L 220C (PE)-PRP 0 ND ND ND ND
P 220C (PE)-PRP 0 ND ND ND ND
aInitial biopsy performed on PRP animals after 1 year of duration; initial biopsy performed on plasma animals after 6 months of
transfusion.
bNT = not transfused.
CND = none detected.
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the media, dialysis patients who characteristically
have elevated serum lipids are at increased risk as
compared to chronically transfused patients.
Blood samples for DEHP analysis were obtained
before dialysis and from venous and arterial lines at
1, 2, 3 and 4 hr and immediately after dialysis.
Samples ofdialysate fluid were obtained from both
the inflow and outflow sites during the indicated
time intervals. The estimated amount of DEHP
received by a patient was calculated from the con-
centration per milliliter of venous blood times the
flow rate multiplied by the duration of dialysis.
As shown in Table 4, DEHP was not demon-
strated in the predialysis venous blood samples. All
patients showed DEHP in the venous blood but
none in the arterial blood during hemodialysis. The
estimated total amount of DEHP delivered to each
patient during a single dialysis varied from32 mgto
90 mg. In one year the estimated total amount of
DEHP received by a patient would range from 120
mg/kgto335mg/kg, adose 10 to20times thatwhich
produced liver abnormalities in the rhesus monkey.
Intensive Plasma Exchange
Intensive plasmaexchanges wereperformed with
an IBM Blood Cell Separator, 5% albumin being
used as replacement fluid. Blood flow rate varied
between 50 and 80 cc/min. Blood samples were
obtained before plasma exchange and at 30, 60, 90
min and at the conclusion of the exchange.
Three patients requiring maintenance plasma
exchange were studied (Table 5). Patient 3 had a
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total lipid level of800 mg-% (cholesterol 240 mg-%,
phospholipids 225 mg-%, triglycerides 335 mg-%).
Theestimatedtotalamount deliveredtoeachpatient
during asingletwo-plasmavolumeplasmaexchange,
varied from 3.3 mg in patients with normal lipid
levelsto 11.6 mginthepatientwithelevatedplasma
lipids. During a single year this patient receives an
estimated 290 mg of DEHP, or 3.3 mg/kg. The
patient has undergone plasma exchange for two
years.
Discussion
The methods used in previously reported studies
call for a more critical assessment of any toxic
hazard created by the use ofphthalate esters, as it
is impossible to establish the significance in man of
in vitro and in vivo studies with an insoluble sub-
stance. The amount ofDEHP leached into platelets
or plasma stored in PVC blood bags is based on the
situation that exists in clinicalmedicine. The rhesus
monkey was chosen as an animal model because its
red cell survival, platelet preservation characteris-
tics, serum protein pattern and DEHP metabolism
are similar to those of the human.
Hepatic disease is often clinically occult due to
theremarkable hepatic functional reserve and regen-
erative capability. The technetium hepatic scintilla-
tion scan is a satisfactory method for visually
recording abnormal function of diminished perfu-
sion. The latter effect results in impaired hepatic
extraction of radioactivity which gives rise to a
nonuniform image (5). In mild forms of parenchy-
Table 4. DEHP plasma concentration during hemodialysis.
DEHP plasma concentration, ,ug/ml
Venous DEHP Estimated total
Patient Prevenous 1 hr 2 hr 3 hr 3.5 hr DEHP received, mg
1 NDa 3.0 3.8 5.0 4.9 90
2 ND 1.8 4.0 3.5 32
3 ND 2.9 2.5 3.2 57
'ND = none detected.
Table 5. DEHP plasma concentration during continuous flow: intensive plasma exchange.a
Plasma DEHP, ,g/ml Estimated total DEHP received, mg
Patient Prevenous 30 min 60 min 90 min Per procedure Per year
1 NDb 2.9 2.6 2.3 3.5 87.5
2 ND 1.7 1.8 2.0 3.3
3 ND 5.7 4.1 3.2 11.6 290.0
'IBM cell separator.
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mal disease, not manifested by irregular distribu-
tion oftracer, changes can be quantitated by deter-
mining the relative distribution of radiocolloid be-
tween liver and spleen (9).
Sulfobromophthalein metabolism and transport
may be evaluated in several ways. The standard
method determines the retention ofBSP ataspecific
interval, usually 45 min after a single injection (10).
A more sensitive technique is the utilization of a
two-compartmental model for the analysis of BSP
kinetics. This was first described in the dog, subse-
quently validated in the human by Quarfordt et al.
and in the rhesus monkey by ourselves. The obser-
vation that the normal BSP disappearance curve in
the child and immature primate is a single exponen-
tial and only changes to a biexponential in the
presence ofliverdisease orwithageis ofsignificance
to the present study (8, 11). At the time this study
was completed, none ofthe rhesus had shed any of
their deciduous teeth, nor had they reached sexual
maturity. Their average weight was 4.54 kg. One of
the monkeys who was part ofthe study to validate
the BSP model had multiple determinations during
a three-year period and converted from a single
exponential to a biexponential. This occurred at
approximately 5.5 years and at a weight of 10.45
kg. The biexponential curves noted in this study
and those seen in children with mild liver disease
differs from those produced by chronic injury in
which the initial slope flattens due to the decrease
in the hepatic removal rate (8).
Eventhough thenumberofanimals in each ofthe
groups is too small for valid statistical analysis, a
trend is observed in the PVC transfused monkeys.
In the present study, prolonged abnormalities in
hepatic scan and BSP kinetics occurred following
DEHP infusion without changes in standard liver
function tests. Six of seven animals had abnormal
99mTc scan ratios, and six of seven demonstrated
abnormal BSP compartmental flow upon comple-
tion of transfusion therapy. These findings have
persisted for up to 14 months following therapy in
three ofthe fourmonkeys given PRP and one ofthe
two monkeys transfused with plasma. Two the the
three remaining monkeys given PRP continued to
have abnormal 'Tc scan ratios 26 months follow-
ingthecessation oftransfusiontherapy. Theresults
of the serial liver biopsies in the PVC transfused
monkeys were quite dramatic and all were abnor-
mal except for the initial biopsy on rhesus "G"
which was normal. Disturbances of hepatic archi-
tecture, the presence ofround-cell infiltration, and
multinucleated giant cells persisted throughout the
follow-up period. The histologic abnormalities have
been reported in apparently normal subhuman pri-
mates. Although none of the animals in this study
had pretreatment biopsies, all seven PVC-transfused
rhesus monkeys and none ofthe six control rhesus
had abnormal histology. The probability of this
being a chance occurrence is highly unlikely.
Although monkeys transfused withplasmastored
in PVC received equivalent doses of DEHP to
those in the PVC-PRP group, their duration of
exposurewassignificantly shorter. Thismayaccount
for the fact that histological changes in liver biopsy
were milderandthattheirliverfunction asreflected
in the kinetics ofBSP transport returned to normal
during the follow-up period.
The results of DEHP quantitation on the serial
liverbiopsiesofthePVCtransfused monkeys shows
a decrease in the residual DEHP content after the
cessation of transfusion. Although we have not as
yet established the metabolic pathway of DEHP in
the rhesus monkey, this finding supports the work
of Daniel et al. who have demonstrated in the rat
and Albro et al. in the African Green monkey that
the DEHP is metabolized in part to mono(2-
ethylhexyl) phthalate (MEHP) (12, 13). This metab-
olite is a potent inhibitor of liver dehydrogenases,
and theoretically may have greater potential for
hepatotoxicity than the parent compound.
Based upon a comparison of the abnormalities
observed in the platelet-rich plasma and plasma
transfused rhesus, alargerdosage over aprolonged
time period appears to be more toxic. This is clini-
cally significant to patients undergoing hemodialy-
sis who yearly are exposed to far greater amounts
ofDEHP thanthat which produced hepatic toxicity
in the rhesus. These patients are more prone to
liver disease which cannot be attributed to the
hepatitis B surface antigen or non-A, non-B hepati-
tis.
PVC medical devices have a high degree of reli-
ability and fabrication technology. While the histo-
logicalandfunctional abnormalitiesinducedbyPVC
plasticized with DEHP in the ranges used in this
study are mild, they were produced at dose levels
observed in transfusion therapy and at lower levels
than those that are observed in hemodialysis.
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